Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

GMZ2-Aluminum Hydroxide Phase I, Tübingen

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by European Malaria Vaccine Initiative.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
European Malaria Vaccine Initiative
ClinicalTrials.gov Identifier:
NCT00397449
First received: November 8, 2006
Last updated: August 9, 2007
Last verified: August 2007

November 8, 2006
August 9, 2007
October 2006
Not Provided
  • Safety [ Time Frame: one year ]
  • Immunogenicity [ Time Frame: one year ]
  • Safety
  • Immunogenicity
Complete list of historical versions of study NCT00397449 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
GMZ2-Aluminum Hydroxide Phase I, Tübingen
Assessment of the Safety and Immunogenicity of the Recombinant Lactococcus Lactis Hybrid GMZ2 [GLURP+MSP3] a Malaria Vaccine in Healthy Adult Volunteers. A Phase I, Double-Blind, Randomised, Dose-Selection, Unicentre Trial

This is a randomized, open, dose-selection Phase 1 study. The study aims to evaluate the safety and immunogenicity of 3 doses (10,30 & 100 micrograms) of the GMZ2 hybrid (GLURP and MSP3) blood stage vaccine in healthy non-immune European adults. The vaccines will be administered with aluminum hydroxide as adjuvant. The safety and the tolerability of the vaccine will be assessed on the rate of solicited and unsolicited events/reactions related to the vaccine. The safety profile will include local and systemic reactions/events as well as the biological safety, based on a clinically significant change of the baseline value of the main biological criteria. The immunogenicity of the different formulation of the vaccine will be assessed on the level and the quality of circulating antibodies as well as the stimulation of the T-cell immune response.

The trial is a randomised, open, dose-selection, single centre trial. One adjuvant will be assessed, aluminum hydroxide (alum). Three different dosages - 10µg, 30µg, and 100µg - of GMZ2 will be evaluated with the aluminum hydroxide adjuvant. A total of 30 volunteers will be enrolled and randomized into three groups of 10. As this is a dose escalation study, volunteers in Group 1 will receive the initial dose of 10µg on the first vaccination day. After a satisfactory safety profile at this dose (see sections 6.2.2 and 6.2.3), we will proceed to vaccinate volunteers in Group 2 with the higher dose of 30µg after a 2-week interval. The same procedure will also be followed for volunteers in Group 3, who will be administered their initial dose of 100µg GMZ2 if the review of the safety profile of Group 2 is satisfactory. The aim will be to recruit all volunteers before the intended start of the study. The randomization procedure will be performed in the following way: when participants are found to be eligible and have signed their informed consent they will be numbered sequentially (in order of enrollment). The numbers will be randomly assigned to 3 groups of 10 numbers through a specific randomization computer program. These groups will be the treatment groups.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Malaria
Biological: GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)
Experimental: 1, 2, 3
Intervention: Biological: GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
December 2007
Not Provided

Inclusion Criteria:

  • Age > 18 and < 45 years healthy volunteers (males or females)
  • General good health based on history and clinical examination
  • All volunteers have to sign the informed consent form
  • Negative pregnancy test
  • Use of adequate contraception for females up to three months after the third injection (D140)
  • Intention to not travel abroad and reachable by phone during the whole study period (15 months).

Exclusion Criteria:

  • History of malaria or residence in malaria endemic areas for the past six months.
  • Positive serology for malaria antigen GLURP and/or MSP3.
  • Previously participated in a malaria vaccine studies.
  • Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers
  • Any laboratory abnormalities on screened blood samples beyond the normal range, as defined at Tübingen. Positive HIV, HBV or HCV tests
  • Volunteers should not be enrolled in any other clinical trial during the whole trial period
  • Volunteers should not receive chronic medication, especially immunosuppressive agents (steroids, immuno-modulating or immunosuppressive drugs) during the three months preceding the screening visit or during the study period
  • Pregnant or lactating women
  • Volunteers unable to give written informed consent
  • Volunteers unable to be closely followed for social, geographic or psychological reasons
  • Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrollment in the study
  • Volunteers should not perform exercise four hours before blood draw and should not donate blood for non study-related purposes during the entire duration of the study
  • Known hypersensitivity to any of the vaccine components (adjuvant or peptide)
  • Volunteers are not allowed to receive any vaccination or gammaglobulin during a period three months prior to the first immunization and up to six months after the 3rd immunization. If a vaccination is necessary during this period, the volunteer will be withdrawn from the study.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00397449
EudraCT: 2005-004568-22
No
Not Provided
European Malaria Vaccine Initiative
Not Provided
Principal Investigator: Jurgen Knobloch, MD Insitut of Tropical Medicine, University of Tubingen
Study Director: Peter Kremsner, MD, PhD Insitut of Tropical Medicine, University of Tubingen
European Malaria Vaccine Initiative
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP